Addex Pharmaceuticals appoints ceo
Bharatt Chowrira has a strong track record in biopharmaceutical industry
Chowrira joins Addex after serving at Nektar Therapeutics, a US biopharmaceutical company developing therapeutics based on advanced polymer conjugate chemistry, as senior vice president and chief operating officer until January this year.
Prior to Nektar, he was executive director, Worldwide Licensing & External Research at Merck & Co. He has also served as vice president of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing.
Addex has also dissolved its transition committee, which was led by Addex vice-chairman Vincent Lawton and included André Mueller and Ray Hill, director. The transition committee was set up as an interim measure following the departure of the former ceo. In addition, Mueller has reverted to the position of non-executive chairman.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Masters of synthesis
Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Regulatory
Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria
Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio